This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jobe, D. A.
Right arrow Articles by Callister, S. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jobe, D. A.
Right arrow Articles by Callister, S. M.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*AMOXICILLIN
*DOXYCYCLINE
*ERYTHROMYCIN
Medline Plus Health Information
*Lyme Disease

 Previous Article  |  Next Article 

Clinical and Diagnostic Laboratory Immunology, November 1999, p. 930-933, Vol. 6, No. 6
1071-412X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.

Detection of Borreliacidal Antibodies in Lyme Borreliosis Patient Sera Containing Antimicrobial Agents

Dean A. Jobe,1 Nenoo Rawal,1,dagger Ronald F. Schell,2,3 and Steven M. Callister1,4,*

Microbiology Research Laboratory1 and Section of Infectious Diseases,4 Gundersen Lutheran Medical Center, La Crosse, Wisconsin 54601, and Wisconsin State Laboratory of Hygiene2 and Department of Medical Microbiology and Immunology,3 University of Wisconsin, Madison, Wisconsin 53706

Received 26 May 1999/Returned for modification 26 July 1999/Accepted 27 August 1999

The borreliacidal-antibody test has been used for the serological detection and confirmation of Lyme borreliosis. However, the presence of antimicrobial agents in serum can confound the accurate detection of borreliacidal antibodies. In this study, we developed a Bacillus subtilis agar diffusion bioassay to detect small concentrations of antimicrobial agents in serum. We also used XAD-16, a nonionic polymeric resin, to adsorb and remove high concentrations of amoxicillin, cefotaxime, ceftriaxone, cefuroxime, doxycycline, and erythromycin without significantly affecting even small concentrations of immunoglobulin M (IgM) or IgG borreliacidal antibodies. High concentrations of penicillin could also be removed by adding 1 U of penicillinase without significantly influencing the levels of borreliacidal antibodies. These simple procedures greatly enhance the clinical utility of the borreliacidal-antibody test.

* Corresponding author. Mailing address: Microbiology Research Laboratory, Gundersen Lutheran Medical Center, 1836 South Ave., La Crosse, WI 54601. Phone: (608) 782-7300, ext. 2042. Fax: (608) 791-6602. E-mail: scallist{at}gc.gundluth.org.

dagger Present address: Department of Biomedical Research, University of Texas Health Science Center, Tyler, TX 75708.

Clinical and Diagnostic Laboratory Immunology, November 1999, p. 930-933, Vol. 6, No. 6
1071-412X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Callister, S. M., Jobe, D. A., Agger, W. A., Schell, R. F., Kowalski, T. J., Lovrich, S. D., Marks, J. A. (2002). Ability of the Borreliacidal Antibody Test To Confirm Lyme Disease in Clinical Practice. CVI 9: 908-912 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»